Company Description
Med-X is currently primarily engaged in the business of supplying environmentally friendly health and wellness products to various industries, including but not limited to the professional pest control industry, over the counter pharmacies through distribution partnerships, as well as directly to consumers.
We strive to be perceived as a health and wellness company offering a series of all-natural and environmentally friendly “green” products and service protocols to other companies and consumers who are also looking to reduce exposure to chemicals and toxins in their personal lives and communities.
Our primary source of revenue is derived from products offered through the following four separate divisions and trade names: Nature-Cide, Thermal-Aid, Malibu Brands and Advertising.
| Country | United States |
| Founded | 2014 |
| Industry | Health Care |
| Sector | Pharmaceuticals |
| Employees | 16 |
| CEO | Matthew Mills |
Contact Details
Address: 8236 Remmet Avenue Canoga Park, CA 91304 United States | |
| Phone | (818) 349-2870 |
| Website | medx-rx.com |
Stock Details
| Ticker Symbol | MXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001620704 |
| Employer ID | 46-5473113 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David E. Toomey | Chief Science Officer |
| Matthew A. Mills | Chairman of the Board and Chief Executive Officer |
| Ronald J. Tchorzewski | Director and Chief Financial Officer |
| Jennifer J. Mills | Director, President and Corporate Secretary |
| Nick Phillips | Chief Media Officer |
| Dr. Morton I. Hyson | Director |
| Dr. Allan Kurtz | Director |
| Fred Dashiell, Jr. | Director |
| Michael Kuntz | Director |
| Dennis Kemmesat | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 11, 2024 | 1-A/A | Filing |
| Oct 3, 2024 | 1-A | Filing |
| Sep 30, 2024 | D/A | Filing |
| Sep 27, 2024 | C/A | Filing |
| Sep 26, 2024 | D | Notice of Exempt Offering of Securities |
| Sep 24, 2024 | 1-SA | Filing |
| Jul 10, 2024 | C/A | Filing |
| Jun 12, 2024 | 1-K/A | Filing |
| May 28, 2024 | C | Filing |
| May 21, 2024 | D | Notice of Exempt Offering of Securities |